Clinical trial / 2016
Hepatic NAD(+) decline occurred with ageing in humans and mice, and oral nicotinamide riboside corrected NAFLD phenotypes in mice.
Investigators compared hepatic NAD(+) and NAD(+) biosynthesis enzymes in middle-aged and aged mice and patients, and tested the effects of high-fat diet and nicotinamide riboside in DN-NAMPT transgenic mice. Hepatic NAD(+) levels decreased in aged mice and humans, with compromised NAMPT-controlled NAD(+) salvage. Middle-aged DN-NAMPT mice fed normal chow displayed systemic NAD(+) reduction and moderate NAFLD phenotypes, which deteriorated under a high-fat diet. Oral administration of nicotinamide riboside completely corrected these NAFLD phenotypes.
- Study type
- Comparative tissue analysis and animal intervention study
- Who was studied
- Middle-aged and aged mice and human patients
- What was measured
- Hepatic NAD(+) levels, NAMPT protein levels, steatosis, inflammation, and fibrosis
THE PAPER
Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing.
Zhou CC, Yang X, Hua X, Liu J, Fan MB, Li GQ, Song J, Xu TY, Li ZY, Guan YF, Wang P, Miao CY. Br J Pharmacol, 2016.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.